IFNG and cancer: Importantly, at least one cancer immunotherapy by activating (IFNγ)(pSTAT1) and inhibiting (TGFβ)(pSTAT3) is currently in preclinical and clinical studies (NCT02786589, NCT03474822, NCT03375983, and NCT05924776).